Press Releases

Printer Friendly Version View printer-friendly version
<< Back
Download PDF Download PDF
Vitae Pharmaceuticals to present at the 30th Annual JP Morgan Healthcare Conference in San Francisco on January 12, 2012

Fort Washington, PA, January 5, 2012 ‐‐ Vitae Pharmaceuticals today announced it will present at the JP Morgan Healthcare Conference on Thursday, January 12, 2012 at 9:30 a.m. Pacific Time in San Francisco, CA. Vitae's President and Chief Executive Officer, Jeffrey Hatfield, will provide an overview on the company and its clinical programs, including VTP‐27999 for chronic kidney disease.

About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical‐stage biopharmaceutical company discovering and developing a portfolio of novel, small molecule, best‐in‐class compounds that address important disease areas, including: chronic kidney disease, diabetes, Alzheimer’s disease and atherosclerosis. Vitae’s lead compound, VTP‐27999, is a wholly owned, novel, potent and selective renin inhibitor offering the potential for superior renal protection in patients suffering from chronic kidney disease. The compound is expected to enter Phase 2b in early 2012.

Vitae is expert in structure‐based drug discovery and combines a proprietary technical platform with the experience and insight of world class scientists to advance best‐in‐class compounds for high value, hard‐to‐drug targets. Vitae’s proprietary, discovery platform has clear advantages in creating and analyzing novel drug candidates that meet pre‐defined physicochemical and biochemical characteristics. The accuracy and speed of this system has enabled Vitae to solve challenging targets in multiple therapeutic areas – discovering and advancing attractive compounds in a rapid and highly capital efficient manner. Vitae Pharmaceuticals is financed by leading corporate and venture capital investors; its last venture round was in 2004. Vitae’s 45 scientists are located in Fort Washington, Pennsylvania. For additional information, please visit the company’s website, www.vitaepharma.com, or contact Burns‐McClellan.

Contacts:
Burns McClellan on behalf of Vitae
Justin Jackson, Michelle Szwarcberg (media)
212‐213‐0006
jjackson@burnsmc.com
mszwarcberg@burnsmc.com